Category: Aggregate Spend Reporting

Explore our library of blogs, insights, research papers, and more information on compliance in the life sciences industry.

The Crucial Role of Technology in Achieving GDPR Compliance

“What Role Is Technology Playing In Helping You Become GDPR Compliant?” We asked this question (or rather, a version of it) during a survey at our recent GDPR Life Sciences Bootcamp. The respondents were uniformly compliance/transparency professionals from the life sciences industry. Any guesses on what their response was? Less than 10% were able to […]

EU Pharma’s Wake-Up Call: Lessons from Insys

A few weeks ago, as we briefly covered news on Insys Therapeutics, we realized that the ripples of its scandal would be felt across the pond. And indeed, qordata finds many compliance professionals in the EU pharma industry voicing concerns about the possibility of something like this happening in their own markets. The fact that […]

Pharma Compliance: From Desk Jobs to Frontline Warriors

There’s a reason business lingo has so much of what I would call ‘war words’: Starting with the all-famous “strategy”, to “target”, “guerilla tactics,” “mission,” “red ocean” and so on. The way I see it, the reason is that in war as in business, rivals compete ruthlessly for the same reward in a challenging and […]

This Life Sciences Company Is About To Get A Spooky Surprise This Christmas

In the American medical drug and device industry, poor compliance practices never go away. They keep coming back to haunt you in newer and more alarming ways. Take Insys Therapeutics, Inc. In less than three years, it has gained infamy for using unethical means (read: violation of good pharmaceutical compliance practices) to sell its opioid, […]

The Evolution of Data Privacy in the EU & USA

Samuel D. Warren and Louis D. Brandeis’ 1890 article “The Right To Privacy” has become classic reading for 21st century data professionals. But as we discovered in an excellent webinar with Denise Farnsworth Chief Privacy Officer, and Senior Corporate Counsel at Jazz Pharmaceuticals, Brandeis’ article forms only half of the data privacy story. What data […]

Debating Transparency Beyond Consent Rates – Part II

The approach towards data privacy in the EU makes consideration towards consent revocation an imperative. If a physician revokes consent, individual versus aggregate spend figures need to be recalculated, and they will show the corresponding changes. Thus, historical consent rate figures may not be an accurate indicator of transparency in that specific market or even […]